172 related articles for article (PubMed ID: 25294053)
1. Progress of hearing loss in neurofibromatosis type 2: implications for future management.
Kontorinis G; Nichani J; Freeman SR; Rutherford SA; Mills S; King AT; Mawman D; Huson S; O'Driscoll M; Gareth Evans D; Lloyd SK
Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3143-50. PubMed ID: 25294053
[TBL] [Abstract][Full Text] [Related]
2. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
3. Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma.
Lustig LR; Yeagle J; Driscoll CL; Blevins N; Francis H; Niparko JK
Otol Neurotol; 2006 Jun; 27(4):512-8. PubMed ID: 16791043
[TBL] [Abstract][Full Text] [Related]
4. Internal Auditory Canal Decompression for Hearing Maintenance in Neurofibromatosis Type 2 Patients.
Bernardeschi D; Peyre M; Collin M; Smail M; Sterkers O; Kalamarides M
Neurosurgery; 2016 Sep; 79(3):370-7. PubMed ID: 26579965
[TBL] [Abstract][Full Text] [Related]
5. Audiologic Natural History of Small Volume Cochleovestibular Schwannomas in Neurofibromatosis Type 2.
deTorres AT; Brewer CC; Zalewski CK; King KA; Walker R; Scott GC; Asthagiri AR; Chittiboina P; Kim HJ
Otol Neurotol; 2018 Mar; 39(3):357-364. PubMed ID: 29342057
[TBL] [Abstract][Full Text] [Related]
6. Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results.
Peyre M; Goutagny S; Bah A; Bernardeschi D; Larroque B; Sterkers O; Kalamarides M
Neurosurgery; 2013 Jun; 72(6):907-13; discussion 914; quiz 914. PubMed ID: 23407292
[TBL] [Abstract][Full Text] [Related]
7. Hearing changes after diagnosis in neurofibromatosis type 2.
Masuda A; Fisher LM; Oppenheimer ML; Iqbal Z; Slattery WH;
Otol Neurotol; 2004 Mar; 25(2):150-4. PubMed ID: 15021775
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
[TBL] [Abstract][Full Text] [Related]
9. Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2.
Tysome JR; Macfarlane R; Durie-Gair J; Donnelly N; Mannion R; Knight R; Harris F; Vanat ZH; Tam YC; Burton K; Hensiek A; Raymond FL; Moffat DA; Axon PR
Otol Neurotol; 2012 Apr; 33(3):466-72. PubMed ID: 22334163
[TBL] [Abstract][Full Text] [Related]
10. Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2.
Choi JW; Lee JY; Phi JH; Wang KC; Chung HT; Paek SH; Kim DG; Park SH; Kim SK
J Neurosurg Pediatr; 2014 Jun; 13(6):650-7. PubMed ID: 24724714
[TBL] [Abstract][Full Text] [Related]
11. Progression of hearing loss in neurofibromatosis type 2 according to genetic severity.
Emmanouil B; Houston R; May A; Ramsden JD; Hanemann CO; Halliday D; Parry A; Mackeith S
Laryngoscope; 2019 Apr; 129(4):974-980. PubMed ID: 30456886
[TBL] [Abstract][Full Text] [Related]
12. Hearing rehabilitation outcomes in cochlear implant recipients with vestibular schwannoma in observation or radiotherapy groups: A systematic review.
Borsetto D; Hammond-Kenny A; Tysome JR; Axon PR; Donnelly NP; Vijendren A; Phillips V; Bance ML
Cochlear Implants Int; 2020 Jan; 21(1):9-17. PubMed ID: 31496442
[No Abstract] [Full Text] [Related]
13. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
14. Significance of cochlear dose in the radiosurgical treatment of vestibular schwannoma: controversies and unanswered questions.
Jacob JT; Carlson ML; Schiefer TK; Pollock BE; Driscoll CL; Link MJ
Neurosurgery; 2014 May; 74(5):466-74; discussion 474. PubMed ID: 24476904
[TBL] [Abstract][Full Text] [Related]
15. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2.
Meijer OW; Vandertop WP; Lagerwaard FJ; Slotman BJ
Neurosurgery; 2008 May; 62(5 Suppl):A37-42; discussion A42-3. PubMed ID: 18580779
[TBL] [Abstract][Full Text] [Related]
16. Vestibular evoked myogenic potentials in neurofibromatosis 2.
Wang CP; Hsu WC; Young YH
Ann Otol Rhinol Laryngol; 2005 Jan; 114(1 Pt 1):69-73. PubMed ID: 15697166
[TBL] [Abstract][Full Text] [Related]
17. Consequences to hearing during the conservative management of vestibular schwannomas.
Walsh RM; Bath AP; Bance ML; Keller A; Rutka JA
Laryngoscope; 2000 Feb; 110(2 Pt 1):250-5. PubMed ID: 10680925
[TBL] [Abstract][Full Text] [Related]
18. Audiologic presentation of vestibular schwannomas in neurofibromatosis type 2.
Lalwani AK; Abaza MM; Makariou EV; Armstrong M
Am J Otol; 1998 May; 19(3):352-7. PubMed ID: 9596188
[TBL] [Abstract][Full Text] [Related]
19. Hearing preservation in vestibular schwannoma management.
Elliott A; Hebb AL; Walling S; Morris DP; Bance M
Am J Otolaryngol; 2015; 36(4):526-34. PubMed ID: 25771841
[TBL] [Abstract][Full Text] [Related]
20. Hearing preservation in neurofibromatosis type 2.
Slattery WH; Brackmann DE; Hitselberger W
Am J Otol; 1998 Sep; 19(5):638-43. PubMed ID: 9752973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
